Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 20/20 | 0.67 |
| ▸ | KDM6B | O15054 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | KDM4A | O75164 | 2/20 | 0.67 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.67 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.64 |
| ▸ | KDM5A | P29375 | 3/20 | 0.57 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15818199 | 1.00 | KDM4C (0.67) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15818587 | 0.86 | TSHR (0.50) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15817727 | 0.85 | KDM4C (0.76) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL1714819 | 0.82 | KDM4C (0.85) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15839861 | 0.81 | KDM4C (0.78) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15825633 | 0.80 | KDM4C (0.76) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15818320 | 0.80 | KDM4C (0.76) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL29582097 | 0.80 | KDM4C (0.76) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15818516 | 0.80 | KDM4C (0.76) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15286753 | 0.78 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | KDM4C 18/4885KDM6B 23/4885KDM4E 26/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | KDM4C 18/4885KDM6B 23/4885KDM4E 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.